Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Zongertinib |
| Trade Name | Hernexeos |
| Synonyms | BI-1810631|BI1810631|BI 1810631 |
| Drug Descriptions |
Hernexeos (zongertinib) is an ERBB2 (HER2) selective inhibitor with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS9143, PMID: 36528522). Hernexeos (zongertinib) is FDA-approved for use in patients with unresectable or metastatic non-squamous non-small cell lung cancer harboring ERBB2 (HER2) tyrosine kinase domain activating mutations (FDA.gov). |
| DrugClasses | HER2 Inhibitor 44 |
| CAS Registry Number | 2728667-27-2 |
| NCIT ID | C189906 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Adagrasib + Zongertinib | Adagrasib Zongertinib | 0 | 0 |
| Ado-trastuzumab emtansine + Zongertinib | Ado-trastuzumab emtansine Zongertinib | 0 | 1 |
| Trastuzumab deruxtecan + Zongertinib | Trastuzumab deruxtecan Zongertinib | 0 | 1 |
| Zongertinib | Zongertinib | 0 | 4 |